Q2 FY2026 EarningsQ2 FY26 missed consensus estimates on profitability and cash flow metrics, reporting a GAAP EPS loss of $0.69 vs. the $0.65 mean expected. R&D spending surged to $39.2M to support the 'dabogratinib 3x3' strategy, driving a deeper-than-expected net loss of $45.6M compared to the $41.1M consensus. While the financial loss widened, the company extended its cash runway into 2H 2028 and confirmed critical Phase 2 data readouts for NMIBC in September 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Tyra Biosciences(TYRA) the Revenue is 0 (--%), Meet estimate;the EBIT is -49 M (-55.8%), Miss estimate;the EPS is -0.69 (-46.81%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B--
0.00B--
0.00B--%
EBITMiss expectations
-0.05B55.80%
-0.04B37.70%
-0.01B18.10%
EPSMiss expectations
-0.6946.81%
-0.651438.60%
-0.03868.21%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf